Novavax (NVAX) Tops Q2 EPS by 210c
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q2 EPS of $0.58, $2.10 better than the analyst estimate of ($1.52). Revenue for the quarter came in at $424.43 million versus the consensus estimate of $237.39 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Park Dental Partners, Inc. (PARK) Tops Q2 EPS by 28c
- Alto Neuroscience, Inc. (ANRO) Tops Q2 EPS by 10c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
